Skip to main content
. 2021 Jul 12;10:e64683. doi: 10.7554/eLife.64683

Table 2. Evidence supporting positive test results indicating presence of virus and impact on other factors.

Strength of evidence for true infection
Higher Moderate Lower p (exact)
Number (col %) (N = 27,879) 21,329 (77%) 4741 (17%) 1809 (6%)
Factors determining classification
Number of genes detected
(row %)
3: 10,317 (48%)
2: 11,012 (52%)
1: 4741 (100%) 1: 1809 (100%)
CT, median 26.2 33.4 34.8
CT, n (row %) <34* 21,070 (98.8%) 3613 (76%) 0 (0%)
Symptoms around test, n (row %) 12,466 (58%) 2243 (47%) 0 (0%) <0.0001
(exc lower)
Occupational risk, n (row %) 1322 (6%) 307 (6%) 0 (0%) 0.48
(exc lower)
Other factors
Cough, fever, anosmia, ageusia around test, n (row %) 9345 (44%) 1241 (26%) 0 (0%) <0.0001
(exc lower)
First positive test n (row %) (vs subsequent positive test) 16,709 (78%) 3508 (74%) 1594 (88%) <0.0001
First test in study, n (row %) (vs follow-up i.e. prior negative in study) 2281 (11%) 482 (10%) 199 (11%) 0.49
Any genome sequence obtained, confirming presence of virus‡ 6,621/9,022 (73%) 544/2,315 (24%) 0/836 (0%) <0.0001
Any other household member ever positive$ 11,493/18,494 (62%) 1,513/4,004 (38%) 318/1,525 (21%) <0.0001

*Approximate 97.5th percentile of CT in higher evidence positives through 2 August 2020 when classification first applied.

Reported working in a patient-facing healthcare role/care/residential home.

Any genome sequence obtained out of attempted (other positives not found or not yet attempted).

$Denominator households with two or more study participants.

Note: Classification arbitrarily determined on 2 August 2020 based on the number of genes detected, Ct values and pre-test probability (see Materials and methods).